GLP-1 receptor agonists and SGLT-2 inhibitors reduce the danger of major cardiovascular events, corresponding to heart attacks and severe liver complications, compared with data presented Sunday at ENDO 2024, the annual meeting of the Endocrine Society. with other diabetes treatments in Boston, Holy Mass.
Prior to this study, there was limited information on the consequences of those specific antidiabetic medications in patients with each type 2 diabetes and fatty liver disease related to metabolic dysfunction (MASLD). Our study shows that GLP-1 receptor agonists and SGLT-2 inhibitors are more useful in stopping heart-related events in comparison with one other class of medicine corresponding to dipeptidyl peptidase 4 inhibitors (DPP-4 inhibitors), and GLP-1 also helps reduce severe hepatic events.”
Alexander Kutz, MD, MPH, MSc., is a research fellow within the Department of Pharmacoepidemiology and Pharmacoeconomics within the Department of Medicine at Brigham and Women’s Hospital and Harvard Medical School in Boston, Massachusetts.
The researchers reviewed Medicare data documented for 2013-2020 and a big U.S. medical insurance database for 2013-2022. They conducted two analyses, including adults with type 2 diabetes and fatty liver disease related to metabolic dysfunction who began GLP-1, SGLT-2 inhibitors, or DPP-4is.
They analyzed the danger of acute heart attack, ischemic stroke, hospitalization for heart failure, or all-cause mortality. Additionally they examined the incidence of great liver-related events.
Individuals who used GLP-1 or SGLT-2 inhibitors had fewer cardiovascular events than those given DPP-4 inhibitors. The researchers also found that GLP-1 reduced the danger of severe liver events in comparison with DPP-4 inhibitors. Furthermore, serious antagonistic events didn’t occur more steadily than with treatment with DPP-4 inhibitors.
Kutz said these findings suggest that GLP-1 receptors and SGLT-2 inhibitors could also be more useful for patients with type 2 diabetes and MASLD than other diabetes medications. As well as, using these drugs, which have grow to be popular in recent times, reduces the danger of cardiac and serious liver complications.
Kutz added that with the introduction of this treatment, patients with type 2 diabetes and MASLD could also be less more likely to be hospitalized despite their complex medical needs.
“An increasing number of individuals have type 2 diabetes, and a major proportion of those people also struggle with MASLD,” Kutz said. “Understanding which medications can effectively treat these conditions and forestall serious complications is critical to their health and quality of life.”